SeaBeLife welcomes Professor Eric Souied to its scientific committee
Download PDF Professor Souied is a renowned ophthalmologist and international expert in AMD (Age-related Macular Degeneration). He will guide the … Lire la suite
Press Release
SeaBeLife enters into joint development agreement with Unither Pharmaceuticals to formulate and produce ophthalmic drug candidate
Download pdf Partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate to treat degenerative … Lire la suite
SeaBeLife secures €2 million – This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs
Download PDF Roscoff, France, October 1, 2025 – SeaBeLife, a biotechnology company developing innovative drug candidates intended to block cellular … Lire la suite
Dry AMD: SeaBeLife achieves highly promising preclinical efficacy results for SBL03, without injections into eye
download PDF SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues … Lire la suite
SeaBeLife receives close to €1.4M deep tech financing from Bpifrance
Funds will enable SeaBeLife to develop pipeline of innovative molecules intended to block programmed cell death in cases of acute … Lire la suite
SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death
SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death. Roscoff, May 17th, 2021. SeaBeLife, … Lire la suite
SeaBeLife Biotech raises € 1.5 million to develop drugs targeting regulated cell death.
SeaBeLife Biotech raises € 1.5 million to develop drugs targeting regulated cell death. Roscoff, June 15, 2020. SeaBeLife, a pharmaceutical … Lire la suite